Can sarcomas benefit from targeted treatments active in other tumour types?
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
New hope for MDM2 inhibition in liposarcomas?
An early-phase trial shows the efficacy of brigimadlin in dedifferentiated and well-differentiated liposarcomas, but confirmation from phase III results is still awaited
Desmoid tumours: nirogacestat improves quality of life also in stable disease
In a post hoc analysis of the DeFi trial, a reduction in symptom burden was reported, with benefits occurring early in treated patients
Should rare cancers still be (in) a niche of oncology?
ESMO is sustaining its efforts to give rare cancers a more prominent place in oncology
Centralisation of care in rare cancers – what are the next steps?
Innovative models and increased cross-border collaborations can further support the implementation of rare cancer reference centres to expedite diagnosis and improve treatment
Studies provide further evidence to support continued imatinib in two different GIST indications
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST
BRCA mutations are associated with worse treatment outcomes in mCRPC
In patients with metastatic castration-resistant prostate cancer, early genetic testing may help personalise treatments in the first-line as a study suggests
A multimodal liquid biopsy analysis shows promise in monitoring response to immunotherapy
A study shows that early kinetics in DNA methylation and fragment quantity in plasma can predict response to pembrolizumab in patients with advanced solid tumours
Most women report poor sexual health after a diagnosis of breast cancer
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
Cancer Research
Use of ctDNA as a surrogate in early clinical drug development – nearing its end point?
Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed